Clinical Trial Update: Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients [Phase 2]

View source ↗

Summary

This update covers a Phase 2 neoadjuvant trial of icotinib in patients with EGFR-mutated non-small cell lung cancer; the current status is unknown and no result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-small-cell Lung Cancer | Phase 2 | Status: UNKNOWN